Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Update

Posted by Sarita Garza on Sep 11th, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 340,186 shares, a drop of 79.3% from the August 15th total of 1,646,299 shares. Approximately 39.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 786,030 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Ratings Changes

VBIO has been the topic of a number of research reports. Wall Street Zen raised Valion Bio, Inc. Common Stock to a “hold” rating in a research note on Saturday, September 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Read Our Latest Analysis on VBIO

Valion Bio, Inc. Common Stock Stock Performance

Valion Bio, Inc. Common Stock stock opened at $2.20 on Friday. The company’s 50-day moving average price is $6.78 and its 200-day moving average price is $16.48. Valion Bio, Inc. Common Stock has a twelve month low of $2.16 and a twelve month high of $80.19. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company has a market cap of $1.96 million, a PE ratio of -0.01 and a beta of 1.79.

About Valion Bio, Inc. Common Stock

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.